Navigation Links
Sirolimus therapy alleviates symptoms of lung disease LAM
Date:3/16/2011

WHAT: Sirolimus, a drug currently used to help prevent transplant rejection, can improve lung function and quality of life in individuals living with the lung disease lymphangioleiomyomatosis (LAM), according to the results of a new study sponsored and conducted in part by the National Heart, Lung, and Blood Institute (NHLBI) of the National Institutes of Health.

"Efficacy and Safety of Sirolimus in Lymphangioleiomyomatosis," will be published online March 16 in the New England Journal of Medicine.

LAM is a rare and progressive lung disease in which cancer-like cells infiltrate the lung, leading to shortness of breath, coughing, chest pain, and in many cases eventual respiratory failure. LAM affects almost exclusively women, primarily of child-bearing age. Though only around 1,000 women in the U.S. have diagnosed LAM, there may be many more as the disease is not well-diagnosed.

This international study, led by the University of Cincinnati, recruited 89 LAM patients to test sirolimus, a drug that can suppress rapid cell growth by blocking an overactive protein called mTOR. Sirolimus is already used as an immune suppressant for organ transplants and is also being tested as a cancer drug. mTOR is also highly active in the invading cells that cause LAM.

The participants took daily oral doses of sirolimus or placebo over 12 months and had their lung function measured at regular intervals. The primary measurement was forced expiratory volume (FEV1), or the volume of air that can be forced out in the first second after taking a deep breath. The sirolimus group displayed stable FEV1 levels over the 12-month treatment period, compared to a roughly 12% decline in the placebo group. The sirolimus group also showed other clinical improvements, and reported a greater ability to carry out day-to-day functions and a better quality of life.

Following the treatment period, the study participants underwent 12-months of observation. After stopping sirolimus, the decline in lung function was similar in both the sirolimus and placebo groups, indicating treatment effectiveness likely requires continued use.


'/>"/>

Contact: NHLBI Communications Office
NHLBI_news@nhlbi.nih.gov
301-496-4236
NIH/National Heart, Lung and Blood Institute
Source:Eurekalert

Related medicine news :

1. Research study explores gene therapy treatment to reduce symptoms of Parkinsons disease
2. University Hospitals Case Medical Center testing innovative heat therapy for premature ejaculation
3. Ohio State study: Targeted ovarian cancer therapy not cost-effective
4. Stroke patients benefit from family involvement in exercise therapy
5. Extra Tests Not a Deterrent to Experimental Cancer Therapy
6. Gene Therapy Against HIV Not a Proven Cure, Experts Say
7. WSU researcher creates patented personalized therapy that causes cancer cells to kill themselves
8. BUSM study shows chemoradiotherapy prior to surgery improves survival
9. Fish oil fights weight loss due to chemotherapy
10. Lack of health insurance limits hepatitis C patients access to latest antiviral therapy
11. Protective strategy shields primate ovaries from radiation-therapy-induced damage
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/7/2016)... ... ... A. Kevin Spann Insurance, a New York-based firm offering insurance and financial ... charity drive to raise funds that will benefit the Marine Corps League. , The ... FMF Corpsmen. Working closely with the MCL, the A. Kevin Spann team plans to ...
(Date:12/7/2016)... ... December 07, 2016 , ... Delete® - Tattoo Removal and Laser Salon Offers ... Season. Save Up To 33% Off Botox® and Juvederm® Products Now Through December 31, ... with Delightful Deals on Botox® and Juvederm® just in time for the ...
(Date:12/7/2016)... ... December 07, 2016 , ... Gensuite is honored to ... the Best New Product Launch category. Gensuite’s entry on their EZ Scan feature ... Global Events & Training Group is a professional event and training provider based ...
(Date:12/7/2016)... ... December 07, 2016 , ... “Walking With God: Inspirational Lessons from My ... the reader to be aware of God's direction in their lives. “Walking With God: ... retired teacher and active church leader. , Sanford says, “I enjoy sharing ...
(Date:12/7/2016)... ... December 07, 2016 , ... NuevaCare, a leading home care agency based ... announce new city-specific pages as part of its ambitious website relaunch. As Bay Area ... first, for local agencies serving their city. The new site has several key city-specific ...
Breaking Medicine News(10 mins):
(Date:12/6/2016)... 2016  Licenders is bringing their 100% all-natural lice removal service ... Slope at 203 13 th Street was specifically chosen to ... "Our goal is to ease parents, stress and bring ... get children right back to class without skipping a beat. The ... safe for the whole family," Licenders President Adie Horowitz ...
(Date:12/6/2016)... 2016 Diabetes & Obesity Drug Development Pipeline ... disease cluster is currently dominated by therapeutics indicated for ... mellitus (T2DM), and the majority of the pipeline, in ... attributable to these indications. While products indicated for obesity ... are a large number of these products in the ...
(Date:12/6/2016)... -- Human Vaccines Market: Scope and Methodology ... wise analysis of the human vaccines market. Stakeholders ... products, raw material suppliers, vaccine processing companies, and ... The report provides qualitative and quantitative analysis of ... market dynamics, trends, product overview, and country-level market ...
Breaking Medicine Technology: